Erasca, Inc. (ERAS) Misses Q4 EPS by 66c

Erasca, Inc. (NASDAQ: ERAS) reported Q4 EPS of ($1.06), $0.66 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Erasca, Inc. (ERAS) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Reading (RDI) Tops Q2 EPS by 4c